From scaling up advanced therapy manufacturing to harnessing the power of digital and automation, Ed Samuel, the new COO of the CGT Catapult, discusses how collaboration and innovation will shape the next phase of the UK’s cell and gene therapy ecosystem.
Last week, the Teesside business community and local guests came together at Wilton Centre, near Redcar, to commemorate the 50th anniversary of the iconic research space, a renowned landmark in Europe’s R&D landscape.
NRG announced the expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; and Kathryn Oliver as Director of Project Management.
Coulter Partners completed a search assignment for Tristel plc (AIM: TSTL) and is pleased to announce the placement of Anna Wasyl as Chief Financial Officer.
Medannex Ltd (Edinburgh) announced the presentation of the first clinical data from the ongoing Phase 1b study of MDX-124, at the European Society for Medical Oncology (ESMO) Congress 2025.
Our third quarter of has been focused on cementing and building upon our influence achieved in the key government policy documents that were published just before summer, such as the industrial Strategy and Life Sciences Sector Plan. Read on for a full breakdown of what they have been doing on your behalf.
Following a landmark TechBio Week, we reflect with some insights from our flagship conference on the transformative potential for growth of technological advances in the sector.
Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 months
A new report published today by the Cell and Gene Therapy Catapult (CGT Catapult) and the Office of Health Economics (OHE) presents a new method of quantifying the economic impact of healthcare innovations, such as cell and gene therapies.
In this blog, Justin Wilson, Withers & Rogers LLP, shares his expert perspective on what the recent patent rulings from the Unified Patent Court (UPC) and the Court of Justice of the European Union (CJEU) mean in practice for biotech and pharma companies.
The Oxford Science Park (TOSP), one of Europe’s leading destinations for science and technology companies, today announced the sale of part of its estate to the Ellison Institute of Technology (EIT).
Find out about how opposition parties are positioning themselves in an increasingly fragmented political landscape, and what it might mean for our sector now and in the long term.
Coulter Partners successfully completed a search assignment Proveca and is pleased to announce the placement of Gregory Reinaud as Chief Operating Officer (COO).
Our latest TechBio: Future-ready biology report confirms a major structural shift in the UK life sciences sector: TechBio has moved from a niche field to the mainstream, accounting for over 40% of all UK biotech deals in recent years.
Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.'
It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch.
